US2010076195A1PendingUtilityA1

Purification of montelukast

58
Assignee: TEVA PHARMAPriority: Jul 5, 2005Filed: Aug 24, 2009Published: Mar 25, 2010
Est. expiryJul 5, 2025(expired)· nominal 20-yr term from priority
Inventors:Greta SterimbaumEvgeny ShapiroKobi Chen
A61P 37/08A61P 11/00A61P 11/02C07D 215/18A61P 11/06
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.

Claims

exact text as granted — not AI-modified
1 - 3 . (canceled) 
   
   
       4 . An isolated impurity, [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-propenyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (MLK-D) of the following structure: 
     
       
         
         
             
             
         
       
     
   
   
       5 - 16 . (canceled)

Join the waitlist — get patent alerts

Track US2010076195A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.